Compare Stocks: GLUE, EWTX, CELC, and DYN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$95.70	$94.58	$44.42 ▼ $151.02	$4.68B	0.19	790,735 shs	515,514 shs
DYN Dyne Therapeutics	$24.28	$24.80	$11.92 ▼ $27.31	$4.53B	1.08	1.69 million shs	1.59 million shs
EWTX Edgewise Therapeutics	$43.07	$42.20	$13.69 ▼ $48.40	$4.68B	0.32	1.13 million shs	824,608 shs
GLUE Monte Rosa Therapeutics	$13.84	$19.05	$4.79 ▼ $25.77	$1.18B	1.5	974,766 shs	804,576 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	+8.21%	+3.14%	+9.46%	+71.84%
DYN Dyne Therapeutics	0.00%	-3.15%	-7.50%	+44.44%	+70.75%
EWTX Edgewise Therapeutics	0.00%	+0.72%	-1.03%	+23.62%	+176.62%
GLUE Monte Rosa Therapeutics	0.00%	+3.44%	-12.85%	-18.59%	+180.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELC Celcuity	$95.70	$94.58	$44.42 ▼ $151.02	$4.68B	0.19	790,735 shs	515,514 shs
DYN Dyne Therapeutics	$24.28	$24.80	$11.92 ▼ $27.31	$4.53B	1.08	1.69 million shs	1.59 million shs
EWTX Edgewise Therapeutics	$43.07	$42.20	$13.69 ▼ $48.40	$4.68B	0.32	1.13 million shs	824,608 shs
GLUE Monte Rosa Therapeutics	$13.84	$19.05	$4.79 ▼ $25.77	$1.18B	1.5	974,766 shs	804,576 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELC Celcuity	0.00%	+8.21%	+3.14%	+9.46%	+71.84%
DYN Dyne Therapeutics	0.00%	-3.15%	-7.50%	+44.44%	+70.75%
EWTX Edgewise Therapeutics	0.00%	+0.72%	-1.03%	+23.62%	+176.62%
GLUE Monte Rosa Therapeutics	0.00%	+3.44%	-12.85%	-18.59%	+180.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELC Celcuity	2.82	Moderate Buy	$154.55	61.49% Upside
DYN Dyne Therapeutics	2.87	Moderate Buy	$34.42	41.75% Upside
EWTX Edgewise Therapeutics	2.82	Moderate Buy	$50.33	16.86% Upside
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	105.92% Upside

Current Analyst Ratings Breakdown

Latest GLUE, EWTX, CELC, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	EWTX Edgewise Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$53.00 ➝ $60.00
8/17/2026	CELC Celcuity	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$165.00 ➝ $175.00
8/17/2026	DYN Dyne Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/17/2026	CELC Celcuity	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/17/2026	CELC Celcuity	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$177.00
8/14/2026	CELC Celcuity	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$155.00
8/14/2026	CELC Celcuity	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$175.00 ➝ $150.00
8/14/2026	CELC Celcuity	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$157.00 ➝ $140.00

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$6.81 per share	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
GLUE Monte Rosa Therapeutics	$123.67M	9.55	N/A	N/A	$3.58 per share	3.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
DYN Dyne Therapeutics	-$446.21M	-$3.33	N/A	N/A	N/A	N/A	-64.30%	-50.33%	11/4/2026 (Estimated)
EWTX Edgewise Therapeutics	-$167.79M	-$1.85	N/A	N/A	N/A	N/A	-39.01%	-36.96%	11/5/2026 (Estimated)
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)

Latest GLUE, EWTX, CELC, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	EWTX Edgewise Therapeutics	-$0.4677	-$0.53	-$0.0623	-$0.53	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million
7/30/2026	Q2 2026	DYN Dyne Therapeutics	-$0.7488	-$1.08	-$0.3312	-$1.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELC Celcuity	6.04	8.93	8.93
DYN Dyne Therapeutics	0.28	12.02	12.02
EWTX Edgewise Therapeutics	N/A	16.24	16.24
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELC Celcuity	63.33%
DYN Dyne Therapeutics	96.68%
EWTX Edgewise Therapeutics	N/A
GLUE Monte Rosa Therapeutics	79.96%

Insider Ownership

Company	Insider Ownership
CELC Celcuity	13.33%
DYN Dyne Therapeutics	9.46%
EWTX Edgewise Therapeutics	21.30%
GLUE Monte Rosa Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELC Celcuity	40	48.93 million	42.41 million	Optionable
DYN Dyne Therapeutics	100	186.75 million	169.08 million	Optionable
EWTX Edgewise Therapeutics	60	108.60 million	85.47 million	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable

GLUE, EWTX, CELC, and DYN Headlines

Recent News About These Companies

Bank of New York Mellon Corp Acquires New Shares in Monte Rosa Therapeutics, Inc. $GLUE

September 5 at 3:14 AM | marketbeat.com

Monte Rosa Therapeutics: High-Stakes Drug Pipeline Balanced By A Fortress Balance Sheet

September 3, 2026 | seekingalpha.com

Monte Rosa Therapeutics, Inc. $GLUE Stock Holdings Decreased by Braidwell LP

September 3, 2026 | marketbeat.com

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

Montanova Capital LLC Sells 677,270 Shares of Monte Rosa Therapeutics, Inc. $GLUE

September 1, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Purchases Shares of 191,877 Monte Rosa Therapeutics, Inc. $GLUE

September 1, 2026 | marketbeat.com

Empowered Funds LLC Purchases Shares of 329,266 Monte Rosa Therapeutics, Inc. $GLUE

August 30, 2026 | marketbeat.com

Nantahala Capital Management LLC Buys Shares of 651,993 Monte Rosa Therapeutics, Inc. $GLUE

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Makes New $25.96 Million Investment in Monte Rosa Therapeutics, Inc. $GLUE

August 29, 2026 | marketbeat.com

Deutsche Bank AG Invests $1.82 Million in Monte Rosa Therapeutics, Inc. $GLUE

August 29, 2026 | marketbeat.com

BlackRock Inc. Purchases New Shares in Monte Rosa Therapeutics, Inc. $GLUE

August 29, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Upgraded at TD Cowen

August 27, 2026 | americanbankingnews.com

615,287 Shares in Monte Rosa Therapeutics, Inc. $GLUE Acquired by Boone Capital Management LLC

August 27, 2026 | marketbeat.com

Bank of America Corp DE Raises Stock Position in Monte Rosa Therapeutics, Inc. $GLUE

August 27, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Up 7.4% on Analyst Upgrade

August 27, 2026 | americanbankingnews.com

Guggenheim Reiterates Buy Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

August 27, 2026 | americanbankingnews.com

ADAR1 Capital Management LLC Buys Shares of 216,752 Monte Rosa Therapeutics, Inc. $GLUE

August 26, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Trading 7.4% Higher on Analyst Upgrade

August 25, 2026 | marketbeat.com

Guggenheim Reaffirms "Buy" Rating for Monte Rosa Therapeutics (NASDAQ:GLUE)

August 25, 2026 | marketbeat.com

Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Rating Upgraded by TD Cowen

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, EWTX, CELC, and DYN Company Descriptions

Celcuity NASDAQ:CELC

$95.70 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Dyne Therapeutics NASDAQ:DYN

$24.28 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Edgewise Therapeutics NASDAQ:EWTX

$43.07 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Monte Rosa Therapeutics NASDAQ:GLUE

$13.84 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, EWTX, CELC, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, EWTX, CELC, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, EWTX, CELC, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, EWTX, CELC, and DYN Company Descriptions

Celcuity NASDAQ:CELC

Dyne Therapeutics NASDAQ:DYN

Edgewise Therapeutics NASDAQ:EWTX

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GLUE, EWTX, CELC, and DYN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GLUE, EWTX, CELC, and DYN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GLUE, EWTX, CELC, and DYN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE, EWTX, CELC, and DYN Company Descriptions

Celcuity NASDAQ:CELC

Dyne Therapeutics NASDAQ:DYN

Edgewise Therapeutics NASDAQ:EWTX

Monte Rosa Therapeutics NASDAQ:GLUE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools